Today, LGC announced the acquisition of Technopath Clinical Diagnostics, a global leader in the development and manufacture of quality control (QC) solutions for clinical laboratories.
1 February 2021, London, UK - Today, LGC announced the acquisition of Technopath Clinical Diagnostics, a global leader in the development and manufacture of quality control (QC) solutions for clinical laboratories.
The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.
Euan O’Sullivan, President & Chief Operating Officer, LGC, said, “We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC. Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”
Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics, commented, “We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit. Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”
Founded in 2004, Technopath Clinical Diagnostics operates from a state-of-the-art facility in Tipperary, Ireland, and currently has more than 100 employees. Its QC and software products are used by leading laboratories in over 120 countries globally.
Technopath Clinical Diagnostics is ISO 13485 certified and has successfully achieved many international regulatory market approvals, including IVD 98/79/EC, Europe CE Mark, US FDA 510K, and accreditations in Canada, China, Brazil and Australia, among others.
Ends)
Notes for editors
About LGC
LGC is a global leader in the life science tools sector, providing mission critical components to customers across clinical diagnostics, pharmaceutical, research & government, food and other applied markets.
LGC provides a comprehensive range of specialty genomic analysis tools, measurement tools and supply chain assurance solutions, underpinned by leading analytical and measurement science capabilities. It holds a number of international roles, including the UK Government Chemist programme and serving as the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement.
LGC’s scientific tools and solutions form an essential part of its customers’ quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research. Its 3,900 employees include internationally-recognised scientists who are experts in their field. Headquartered in London, LGC operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.
LGC was founded in 1842. It has been privately-owned since 1996 and has diversified through internal investment and acquisitions to be an international leader in its chosen markets. LGC is now owned by funds affiliated to Cinven, Astorg and ADIA.
For more information, please visit www.lgcgroup.com
About LGC Clinical Diagnostics
LGC’s Clinical Diagnostics business unit develops and manufactures a comprehensive portfolio of catalogue and custom-developed diagnostic quality solutions and component materials for the clinical market. We partner with IVD assay developers, and pharmaceutical, CRO and academic institutions in commercialisation activities across the entire diagnostic pipeline - from concept and early stage research, through expedited product development and onwards into routine clinical use. Laboratorians and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics rely on LGC’s products to support accurate and reliable diagnostic results.
Our operating entities include SeraCare Life Sciences and Maine Standards Company, which are manufacturers of quality control tools (calibrators, controls, linearity products and EQA/PT samples) for the IVD industry and the Native Antigen Company, which is a manufacturer and supplier of viral antigens. Our 200+ employees operate FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland, USA, and an ISO 9001-accredited facility in Oxford, UK.
Each day, our world-class staff, scientific expertise, operational efficiency and superior quality systems are ready to support the range of advanced technologies that collectively improve patient outcomes - from the widely adopted and established through to cutting-edge NGS and precision diagnostics.
Media contact details
LGC
Julian Quigley
Media Relations & Social Media Manager
+44 (0)20 8943 8491
